Guardian Pharmacy raises 2026 outlook to $1.43B-$1.45B revenue and $129M-$131M adjusted EBITDA amid IRA pricing pressure (NYSE:GRDN)
· seekingalpha.com
Guardian Pharmacy (GRDN) Q2 2026 earnings call: raised 2026 guidance, IRA pricing headwinds, EBITDA resilience, M&A/greenfield growth and risks—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...